Talphera (TLPH) Competitors $0.48 +0.02 (+3.25%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. XFOR, KPTI, NRXP, ATRA, HOWL, ESLA, COEP, KZR, RVPH, and MRNSShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include X4 Pharmaceuticals (XFOR), Karyopharm Therapeutics (KPTI), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), Werewolf Therapeutics (HOWL), Estrella Immunopharma (ESLA), Coeptis Therapeutics (COEP), Kezar Life Sciences (KZR), Reviva Pharmaceuticals (RVPH), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical products" industry. Talphera vs. X4 Pharmaceuticals Karyopharm Therapeutics NRx Pharmaceuticals Atara Biotherapeutics Werewolf Therapeutics Estrella Immunopharma Coeptis Therapeutics Kezar Life Sciences Reviva Pharmaceuticals Marinus Pharmaceuticals Talphera (NASDAQ:TLPH) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership. Do analysts prefer TLPH or XFOR? Talphera currently has a consensus target price of $4.33, indicating a potential upside of 800.90%. X4 Pharmaceuticals has a consensus target price of $2.83, indicating a potential upside of 1,384.98%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Talphera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in TLPH or XFOR? 37.7% of Talphera shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 3.2% of Talphera shares are owned by insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, TLPH or XFOR? Talphera has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Does the MarketBeat Community prefer TLPH or XFOR? X4 Pharmaceuticals received 69 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 68.10% of users gave X4 Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTalpheraOutperform Votes10100.00% Underperform VotesNo VotesX4 PharmaceuticalsOutperform Votes7968.10% Underperform Votes3731.90% Is TLPH or XFOR more profitable? Talphera's return on equity of -118.46% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -118.46% -65.82% X4 Pharmaceuticals N/A -236.19%-75.14% Does the media favor TLPH or XFOR? In the previous week, Talphera and Talphera both had 1 articles in the media. Talphera's average media sentiment score of 1.00 beat X4 Pharmaceuticals' score of 0.00 indicating that Talphera is being referred to more favorably in the media. Company Overall Sentiment Talphera Positive X4 Pharmaceuticals Neutral Which has stronger valuation and earnings, TLPH or XFOR? Talphera has higher earnings, but lower revenue than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$281K29.27-$18.40M-$0.51-0.94X4 Pharmaceuticals$2.56M12.96-$101.17M-$0.19-1.00 SummaryTalphera beats X4 Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.22M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E Ratio-0.706.9521.9417.81Price / Sales29.27231.03380.9597.68Price / CashN/A65.6738.2634.64Price / Book0.585.936.453.98Net Income-$18.40M$143.22M$3.22B$247.81M1 Month Performance-21.26%-13.56%-9.76%-7.91%1 Year Performance-51.41%-8.89%11.49%1.53% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera2.8601 of 5 stars$0.48+4.3%$4.33+800.9%-53.3%$8.22M$281,000.00-0.7019Short Interest ↓Positive NewsGap UpXFORX4 Pharmaceuticals4.2747 of 5 stars$0.20-2.5%$2.83+1,283.5%-84.1%$35.57M$2.56M-2.2880KPTIKaryopharm Therapeutics3.1255 of 5 stars$4.21-1.9%$57.50+1,265.8%-74.2%$35.44M$145.24M-4.13380Short Interest ↑Negative NewsHigh Trading VolumeNRXPNRx Pharmaceuticals1.5881 of 5 stars$2.03-1.0%$28.25+1,291.6%-36.1%$34.68MN/A-0.952Short Interest ↑Negative NewsATRAAtara Biotherapeutics3.9617 of 5 stars$5.85+5.8%$17.75+203.4%-64.3%$34.28M$128.94M-0.23330News CoverageHOWLWerewolf Therapeutics2.8536 of 5 stars$0.77+8.7%$9.00+1,066.1%-84.3%$31.83M$1.89M-0.5040News CoverageGap UpESLAEstrella Immunopharma2.7819 of 5 stars$0.87+0.7%$16.00+1,728.8%-23.0%$31.64MN/A-3.37N/AShort Interest ↓Positive NewsGap UpCOEPCoeptis Therapeutics0.4339 of 5 stars$9.40flatN/A+40.9%$31.63MN/A-1.622Short Interest ↑News CoverageKZRKezar Life Sciences3.741 of 5 stars$4.32+9.4%$39.50+814.4%-47.2%$31.56M$7M-0.3360RVPHReviva Pharmaceuticals2.283 of 5 stars$0.78+15.0%$10.00+1,188.5%-74.1%$31.54MN/A-0.705Upcoming EarningsMRNSMarinus Pharmaceuticals2.1399 of 5 stars$0.55-0.2%$4.79+771.6%-61.1%$30.32M$30.99M-0.22110Analyst ForecastNews Coverage Related Companies and Tools Related Companies X4 Pharmaceuticals Alternatives Karyopharm Therapeutics Alternatives NRx Pharmaceuticals Alternatives Atara Biotherapeutics Alternatives Werewolf Therapeutics Alternatives Estrella Immunopharma Alternatives Coeptis Therapeutics Alternatives Kezar Life Sciences Alternatives Reviva Pharmaceuticals Alternatives Marinus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
